Logo Logo
Help
Contact
Switch Language to German
Schneider, Lina S.; Ulrich, Melanie; Lehr, Thorsten; Menche, Dirk; Müller, Rolf; Schwarzenberg, Karin von (2016): MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition. In: Molecular Oncology, Vol. 10, No. 7: pp. 1054-1062
Full text not available from 'Open Access LMU'.

Abstract

Treating cancer is one of the big challenges of this century and it has become evident that single chemotherapeutic treatment is rarely effective. As tumors often carry multiple mutations using combination therapy which addresses different targets seems therefore more beneficial. One of the most frequently mutated genes in tumors is the tumor suppressor p53. Significant work has been put in the development of p53 activators, which are now in clinical studies against diverse cancers. Recently, we could show that inhibition of V-ATPase, a multi subunit proton pump, by archazolid induces p53 protein levels in cancer cells. In this study, we provide evidence that the combination of archazolid with the p53 activator nutlin-3a is synergistically inducing cell death in different p53 wild type tumor cell lines. Mechanistically, this effect could presumably be attributed to reduction of glycolysis as TIGAR mRNA levels were increased and glucose uptake and Glut1 protein levels were reduced. In addition, combination treatment highly activated pro-apoptotic pathways including IGFBP3 and Bax inducing caspase-9 and PARP cleavage. Remarkably, combination of archazolid and nutlin3a was more efficient in reducing tumor growth compared to single dose treatment in a U87MG mouse model in vivo. Hence, our findings suggest the combination of archazolid and nutlin-3a as a highly promising strategy for the treatment of p53 wild type tumors. (C) 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.